Drilon, A., Siena, S., Ou, S. I., Patel, M., Ahn, M. J., Lee, J., . . . De Braud, F. G. (2017). Safety and Antitumor Activity of the Multi-Targeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib (RXDX-101): Combined Results from Two Phase 1 Trials (ALKA-372-001 and STARTRK-1). Cancer Discov.
Chicago ZitierstilDrilon, Alexander, et al. "Safety and Antitumor Activity of the Multi-Targeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib (RXDX-101): Combined Results From Two Phase 1 Trials (ALKA-372-001 and STARTRK-1)." Cancer Discov 2017.
MLA ZitierstilDrilon, Alexander, et al. "Safety and Antitumor Activity of the Multi-Targeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib (RXDX-101): Combined Results From Two Phase 1 Trials (ALKA-372-001 and STARTRK-1)." Cancer Discov 2017.